Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 51 - 56 of 56

Selected Filters:
7 July 2022

Descovy for PrEP

The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.

Normative Guidance/Policies

External Link
7 July 2022

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

This article announces the U.S. Food and Drug Administration's approval of Descovy in at-risk adults and adolescents for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection from sex, excluding those who have receptive vaginal sex.

Normative Guidance/Policies

External Link
7 July 2022

Descovy for PrEP – FDA Supplemental Approval

This letter from the US Food and Drug Administration outlines supplemental approval granted to Descovy, an oral PrEP medication.

Normative Guidance/Policies

External Link
24 July 2020

Guidance for the Use of Pre-exposure Prophylaxis (PrEP) for the Prevention of HIV Acquisition in British Columbia

These guidelines were developed by the British Columbia Centre for Excellence in HIV/AIDS and focus on the provision of PrEP as a part of a comprehensive approach to combination prevention, drawing on implementation and research evidence and WHO recommendations.

Normative Guidance/Policies

Document
17 December 2018

PrEP for the Prevention of HIV Infection of HIV Infection in the United States – 2017 Update

Preexposure Prophylaxis for HIV Prevention in the United States – 2017 Update: A Clinical Practice Guideline provides comprehensive information for the use of daily oral antiretroviral preexposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection in adults.

Normative Guidance/Policies

Document
17 December 2018

National HIV/AIDS Strategy for the United States (2015 – 2020)

The nation’s comprehensive strategy for HIV/AIDS prevention and treatment.

Normative Guidance/Policies

Document